首页 | 本学科首页   官方微博 | 高级检索  
     


Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label,randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group
Authors:Hans Wildiers  Konstantinos Tryfonidis  Lissandra Dal Lago  Peter Vuylsteke  Giuseppe Curigliano  Simon Waters  Barbara Brouwers  Sevilay Altintas  Nathan Touati  Fatima Cardoso  Etienne Brain
Affiliation:1. Department of General Medical Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium;2. European Organization for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium;3. Department of Medicine, Institut Jules Bordet, Brussels, Belgium;4. Centre Hospitalier Universitaire, Université Catholique de Louvain, Namur, Belgium;5. Department of Hematology and Oncology, Division of Early Drug Development, University of Milano, Istituto Europeo di Oncologia, Milan, Italy;6. Velindre Cancer Centre, Cardiff, UK;7. Department of Medical Oncology, AZ Sint-Jan Hospital, Bruges, Belgium;8. Department of Medical Oncology, Antwerp University Hospital, Antwerp, Belgium;9. Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal;10. Department of Medical Oncology, Institut Curie (Hôpital René Huguenin) Saint-Cloud, France
Abstract:
Keywords:Correspondence to: Dr Hans Wildiers   Department of General Medical Oncology   University Hospitals Leuven and Department of Oncology   KU Leuven   Herestraat 49   B-Leuven   Belgium
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号